Oncolytics Biotech Inc ONCY

Merck' anti-PD-1 Keytruda fails as a monotherapy with chemo

[Noteable]

May 09, 2024 - "Used as an adjuvant treatment with chemotherapy, with or without radiotherapy for newly diagnosed high-risk patients, the anti-PD-1 treatment did not meet the primary endpoint of disease-free survival compared to placebo at the interim analysis."

That announcement came on the heels of back-to-back Keytruda failures in non-small cell lung cancer (NSCLC). In December, the company announced that combined with its experimental anti-TIGIT antibody vibostolimab, the anti-PD1 failed to improve progression free survival in NSCLC patients. The same day, a trial of Keytruda plus AstraZeneca’s Lynparza failed to elicit significant improvement in overall survival in metastatic squamous NSCLC. Then, in March, the company announced that the Lynparza combination fell short of dual primary endpoints in specific patients with metastatic non-squamous NSCLC. 

https://www.biospace.com/article/keytruda-strikes-out-again-for-endometrial-cancer-with-phase-iii-fail-/

[Noteable]

ONCY's drug platfrom pelareorep "primes" the immune system and remodels the tumor microenvironment (TME) in advance of the addition of an immune checkpoint inhibitor, like Merck's Keytruda, resulting in the synergistic effectiveness in the combined effort of both pelareorep AND the immune checkpoint inhibitor in the treatment of cancer.

[Noteable]

August 29, 2024 - Merck's checkpoint inhibitor Keytruda fails as a monotherapy when added to radiation treatment. During a planned interim analysis, Keytruda’s addition to radiation not only failed to improve patients’ risk of disease worsening or death, but it led to higher rates of adverse events, including ones that resulted in death, Merck said.   In addition, a combination of

[Noteable]

May 09, 2024 - "Used as an adjuvant treatment with chemotherapy, with or without radiotherapy for newly diagnosed high-risk patients, the anti-PD-1 treatment did not meet the primary endpoint of disease-free survival compared to placebo at the interim analysis." That announcement came on the heels of back-to-back Keytruda failures in non-small cell lung cancer (NSCLC

[fasttrack5]

This been said. ONCY's drug platfrom pelareorep "primes" the immune system and remodels the tumor microenvironment (TME) in advance of the addition of an immune checkpoint inhibitor, like Merck's Keytruda, resulting in the synergistic effectiveness in the combined effort of both pelareorep AND the immune checkpoint inhibitor in the treatment of cancer  When Will Merck take a

[Noteable]

ONCY's drug platfrom pelareorep "primes" the immune system and remodels the tumor microenvironment (TME) in advance of the addition of an immune checkpoint inhibitor - subsequently turning 'cold" tumors 'hot' -  as per the represented approach  .... https://www.researchgate.net/figure/Approaches-to-turn-a-cold-tumor-into-a-hot-tumor-Some-representative